WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
Status:
Not yet recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, prospective, open-label, phase II trial. Patients with suspected
advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation
and evaluation of disease spread will be registered into the trial after providing a 1st
written informed consent.